NMS · Biotechnology
BCRX (BCRX) Stock
$10.17
+2.52%
NMS: BCRX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
GlobeNewswire · Jul 15, 2026
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
Zacks · Jul 14, 2026
BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers
Simply Wall St. · Jul 9, 2026
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?
Stocktwits · Jul 9, 2026
BioCryst Pharmaceuticals (BCRX) Ends Internal Discovery And Closes Birmingham Facility
Simply Wall St. · Jul 9, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held1.20%
Institutions Held100.25%
Institutions Float Held101.47%
Peer Comparison
About BCRX
BCRX stock trades at $10.17 with a market capitalization of $2.58B. The stock is valued at a price-to-earnings (P/E) ratio of -7.07, price-to-book of -5.70, price-to-sales of 2.75. Over the past 52 weeks the stock has ranged between $6.00 and $11.22, and currently trades 9.4% below its 52-week high.
On profitability, BCRX generates a return on equity (ROE) of 101.55% — well above the market average, a sign of a high-quality business, return on capital employed of -89.73%, an operating margin of 38.97%, a net profit margin of -40.90%.